Biomimetic Drug Delivery

A leukosome is a biomimetic nanovesicle synthesized by leukocyte membrane proteins combined with biocompatible phospholipids and cholesterol. The leukosome approach represents a breakthrough in the nanomanufacturing field. For the first time, a complex material such as the plasma membrane is formulated into liposome-like vesicles using a unique, one-step synthesis method, while retaining the high versatility of liposomal formulations. The transfer of leukocyte membrane proteins on a leukosome surface allows these vesicles to evade the mononuclear phagocytic system clearance and to preferentially target the inflamed vasculature. Inflammation is the common denominator among a number of pathologies. The research team envisions using leukosomes as the ultimate personalized therapy in all the diseases that share an inflammatory background, including cardiovascular, autoimmune, and neurological diseases, diabetes and cancer.

Cardiac Regeneration

We deal with cardiac cell regeneration for treatment of congenital heart defects and other cardiovascular diseases. We address these through cardiac patches using induced pluripotent stem cells (iPSCs) and biomimetic scaffolds. We use iPSCs derived from skin biopsies and bone marrow to provide a replenishable source of autologous cells for cardiac differentiation. Our focus includes:

  • Controlled particle release patches for cardiomyocyte differentiation
  • Aligned, conductive scaffolds via electrospinning for cardiomyocyte maturation
  • Cardiac conduction cell differentiation via molecular cues
  • Cardiac maturation through electromechanical cues

Cancer Nanotherapeutics

Based on previous lab successes, we have developed a powerful tool for use in the identification and characterization of the processes in our model system. A major advantage of this development is its improved sensitivity, which allows it to detect subtle dynamic property changes in response to our experimentation.
Live Chat Available